Dimerix Ltd has released a press release.
Dimerix Successfully Passes Efficacy Interim Analysis
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Dimerix
- PH3 Data Collection Complete for First Interim Analysis
- Half-Year Financial Report & Appendix 4D - 31 December 2023
- ACTION3 IND Approved in China
- Dimerix Receives Initial Upfront Payment from Advanz Pharma
- Dimerix Announces License Agreement for EU, Canada, ANZ
Later from Dimerix
- Dimerix Completes $20M Placement
- Dimerix Receives PIP Approval from the UK MHRA
- Dimerix and Taiba enter into License Agreement for DMX-200
- Adolescent Recruitment into ACTION3 Clinical Trial
- Preliminary Final Report
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix